B-Cell Malignancies: The Use of Small Molecule Agents for Treatment and Management.

B-Cell Malignancies: The Use of Small Molecule Agents for Treatment and Management. Clin J Oncol Nurs. 2020 Apr 01;24(2):199-204 Authors: Rogers BB Abstract Hematologic B-cell malignancies, which have varying behavior patterns, disease processes, and treatment responses, include non-Hodgkin lymphoma, leukemias, and myeloma. Although monoclonal antibodies and other agents have led to dramatic advances in the treatment of B-cell malignancies, the development of small molecules have enhanced the ability to treat and manage these malignancies and their adverse events (AEs). Oncology nurses need to be educated on the unique side effects for each class of these agents so that they can administer interventions to prevent and manage AEs in patients. PMID: 32196006 [PubMed - as supplied by publisher]
Source: Clinical Journal of Oncology Nursing - Category: Nursing Authors: Tags: Clin J Oncol Nurs Source Type: research